OBJECT: The aim of this study was to examine tumor volume as a prognostic factor for patients with brain metastases treated with Gamma Knife surgery (GKS). METHODS: Two hundred fifty patients with 1-14 brain metastases who had initially undergone GKS alone at a single institution were retrospectively reviewed. Patients who received upfront whole brain radiation therapy were excluded. Survival times were estimated using the Kaplan-Meier method. Univariate and multivariate analyses using Cox proportional hazard regression models were used to determine if various prognostic factors could predict overall survival, distant brain failure, and local control. RESULTS: Median overall survival was 7.1 months and the 1-year local control rate was 91.5%. Median time to distant brain failure was 8.0 months. On univariate analysis an increasing total tumor volume was significantly associated with worse survival (p = 0.031) whereas the number of brain metastases, analyzed as a continuous variable, was not (p = 0.082). After adjusting for age, Karnofsky Performance Scale score, and extracranial disease on multivariate analysis, total tumor volume was found to be a better predictor of overall survival (p = 0.046) than number of brain metastases analyzed as a continuous variable (p = 0.098). A total tumor volume cutoff value of ≥ 2 cm(3) (p = 0.008) was a stronger predictor of overall survival than the number of brain metastases (p = 0.098). Larger tumor volume and extracranial disease, but not the number of brain metastases, were predictive of distant brain failure on multivariate analysis. Local tumor control at 1 year was 97% for lesions < 2 cm(3) compared with 75% for lesions ≥ 2 cm(3) (p < 0.001). CONCLUSIONS: After adjusting for other factors, a total brain metastasis volume was a strong and independent predictor for overall survival, distant brain failure, and local control, even when considering the number of metastases.
OBJECT: The aim of this study was to examine tumor volume as a prognostic factor for patients with brain metastases treated with Gamma Knife surgery (GKS). METHODS: Two hundred fifty patients with 1-14 brain metastases who had initially undergone GKS alone at a single institution were retrospectively reviewed. Patients who received upfront whole brain radiation therapy were excluded. Survival times were estimated using the Kaplan-Meier method. Univariate and multivariate analyses using Cox proportional hazard regression models were used to determine if various prognostic factors could predict overall survival, distant brain failure, and local control. RESULTS: Median overall survival was 7.1 months and the 1-year local control rate was 91.5%. Median time to distant brain failure was 8.0 months. On univariate analysis an increasing total tumor volume was significantly associated with worse survival (p = 0.031) whereas the number of brain metastases, analyzed as a continuous variable, was not (p = 0.082). After adjusting for age, Karnofsky Performance Scale score, and extracranial disease on multivariate analysis, total tumor volume was found to be a better predictor of overall survival (p = 0.046) than number of brain metastases analyzed as a continuous variable (p = 0.098). A total tumor volume cutoff value of ≥ 2 cm(3) (p = 0.008) was a stronger predictor of overall survival than the number of brain metastases (p = 0.098). Larger tumor volume and extracranial disease, but not the number of brain metastases, were predictive of distant brain failure on multivariate analysis. Local tumor control at 1 year was 97% for lesions < 2 cm(3) compared with 75% for lesions ≥ 2 cm(3) (p < 0.001). CONCLUSIONS: After adjusting for other factors, a total brain metastasis volume was a strong and independent predictor for overall survival, distant brain failure, and local control, even when considering the number of metastases.
Authors: Ammoren E Dohm; Ryan Hughes; William Wheless; Michael Lecompte; Claire Lanier; Jimmy Ruiz; Kounosuke Watabe; Fei Xing; Jing Su; Christina Cramer; Adrian Laxton; Stephen Tatter; Michael D Chan Journal: J Neurooncol Date: 2018-10-26 Impact factor: 4.130
Authors: Or Cohen-Inbar; Patrick Melmer; Cheng-chia Lee; Zhiyuan Xu; David Schlesinger; Jason P Sheehan Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130
Authors: Michael C LeCompte; Emory McTyre; Adrianna Henson; Michael Farris; Catherine Okoukoni; Christina K Cramer; Pierre Triozzi; Jimmy Ruiz; Kounosuke Watabe; Hui-Wen Lo; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Xiaobo Zhou; Michael Chan Journal: Cureus Date: 2017-12-11
Authors: Kyung Rae Cho; Min Ho Lee; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Sung Tae Kim; Do Hun Lim; Jung-Il Lee Journal: J Neurooncol Date: 2015-09-15 Impact factor: 4.130
Authors: Timothy B Stokes; Ajay Niranjan; Hideyuki Kano; Phillip A Choi; Douglas Kondziolka; L Dade Lunsford; Edward A Monaco Journal: J Neurooncol Date: 2014-12-02 Impact factor: 4.130
Authors: Carmine Antonio Donofrio; Andrea Cavalli; Marco Gemma; Lucia Riccio; Alessandra Donofrio; Pietro Panni; Camillo Ferrari da Passano; Antonella Del Vecchio; Angelo Bolognesi; Riccardo Soffietti; Pietro Mortini Journal: Clin Exp Metastasis Date: 2020-05-19 Impact factor: 5.150
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300